Results 211 to 220 of about 9,843,661 (289)

Otolaryngology Workforce Projections in the United States, 2021-2036. [PDF]

open access: yesLaryngoscope Investig Otolaryngol
Berisha L   +10 more
europepmc   +1 more source

Remaining Burden of Spinal Muscular Atrophy Among Treated Patients: A Survey of Patients and Caregivers

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Spinal muscular atrophy (SMA) significantly impacts motor function. This study aimed to assess the persistent burden and unmet needs among currently treated patients with SMA and their caregivers. Methods Two complementary web‐based surveys were distributed in August 2024 among patients with SMA and their caregivers.
Julie A. Parsons   +8 more
wiley   +1 more source

Discovery and Treatment of Action Potential‐Independent Myotonia in Hyperkalemic Periodic Paralysis

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Hyperkalemic periodic paralysis (hyperKPP) is characterized by attacks of transient weakness. A subset of hyperKPP patients suffers from transient involuntary contraction of muscle (myotonia). The goal of this study was to determine mechanisms causing myotonia in hyperKPP.
Chris Dupont   +4 more
wiley   +1 more source

Durable B‐Cell Impairment While Sparing IgA B Cells After Ocrelizumab Therapy in Multiple Sclerosis

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objectives Ocrelizumab (OCR), a humanized anti‐CD20 monoclonal antibody, is highly efficient in relapsing–remitting multiple sclerosis (RR‐MS). We assessed early cellular B‐cell profiles in patients prior to OCR treatment, on OCR treatment, and after 15 months of therapy discontinuation.
Alexandra Garcia   +20 more
wiley   +1 more source

Virtual Pulmonary Rehabilitation in the United States: Clinical Practice Experience. [PDF]

open access: yesAnn Am Thorac Soc
Bryant MS   +3 more
europepmc   +1 more source

Circulating Interleukin‐6 Levels and Timing of Acute Ischemic Stroke Onset

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Intravenous thrombolysis is the most widely available effective ischemic stroke treatment, but is approved only if given within 4.5 h from stroke onset. Many patients are not treated because stroke onset time is unknown. We evaluated the cytokine interleukin 6 (IL‐6) in circulating blood after acute ischemic stroke (AIS).
Robert G. Kowalski   +15 more
wiley   +1 more source

The Road Not Taken: Misclassifying an Anti‐Seizure Medication as a Failure

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To quantify how often anti‐seizure medications (ASMs) appear ineffective yet provide benefit when considering seizure frequency (SF) variability. Methods We used the CHOCOLATES seizure diary simulator to generate 100,000 patient seizure diaries that reflect natural SF variation in a heterogeneous population.
Christopher N. Henry   +1 more
wiley   +1 more source

Home - About - Disclaimer - Privacy